Blog Our latest articles from the Alliance of U.S. Startups and Inventors for Jobs The Special 301 Report is Only the Beginning. Now Comes the Hard Part August 4, 2026 The Trump administration’s 2026 Special 301 Report marks an important shift in how the U.S. approaches intellectual property. For the… Washington must defend America’s biotech ecosystem July 2, 2026 For decades, America’s biotechnology leadership has relied on an innovation ecosystem where startups, university researchers, entrepreneurs, and investors work together… USIJ urges lawmakers to reject the ETHIC Act June 8, 2026 Last week, the House Judiciary Committee held a hearing on “Medicines and IP: Balancing Innovation and Access.” The conversation had… Takeaways from this year’s Special 301 Report May 18, 2026 The Office of the United States Trade Representative last month released its 2026 Special 301 Report, directly confronting a problem… Germany’s Health Reforms Should Concern Anyone Who Cares About Innovation May 5, 2026 Germany has announced a new set of health care reforms to close a growing budget gap. At their core, these… The ETHIC Act and the Risk to American Innovation April 3, 2026 In Washington, a simple narrative has taken hold: if drug prices are too high, patents must be the problem. That… When Policy Reform Doesn’t Reach the Panel: Why PTAB Consistency Matters March 25, 2026 This month, the Alliance of U.S. Startups and Inventors for Jobs (USIJ) released a new policy brief highlighting a critical issue… Protecting American Innovation: Why PTAB Reform Is Needed March 5, 2026 For more than a decade, many U.S. startups and small innovators have faced a growing challenge in protecting their intellectual… Debunking the “serial patent” myth February 26, 2026 Groups like CSRxP and Patents for Affordable Drugs NOW have recently ramped up their rhetoric on pharmaceutical patents. Having long… Restoring Patent Eligibility Is Essential to Supporting American Startups and Inventors February 11, 2026 As we look ahead to the year, the Alliance of U.S. Startups and Inventors for Jobs has identified a focused… Rethinking the “Patent Thicket Narrative” in Biopharma February 4, 2026 Over the past few months, we’ve read no shortage of analyses about why prescription drugs cost what they do. Some… The “patent thicket” narrative misunderstands innovation January 21, 2026 A familiar claim keeps resurfacing in discussions about drug pricing: that companies use “patent thickets” to game the system and…
